β-blockers in the management of hypertension: focus on nebivolol

References

• Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States, 1999 to 2000: a rising tide. Hypertension44, 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. J. Am. Med. Assoc.290, 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch. Intern. Med.161, 1183–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the USA: findings from the Third National Health and Nutrition Examination Survey (1988–1994). Arch. Intern. Med.161, 1207–1216 (2001).
   PubMed Web of Science ®Google Scholar
• Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am. J. Hypertens.7(7 Pt 2), S7–S12 (1994).
   Google Scholar
• Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J.25, 1341–1362 (2004).
   PubMed Web of Science ®Google Scholar
• Ubel PA, Jepson C, Asch DA. Misperceptions about β-blockers and diuretics: a national survey of primary care physicians. J. Gen. Intern. Med.18, 977–983 (2003).
   PubMed Web of Science ®Google Scholar
• Ko DT, Hebert PR, Coffey CS et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J. Am. Med. Assoc.288, 351–357 (2002).
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am. J. Hypertens.11, 1258–1265 (1998).
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet364, 1684–1689 (2004).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366, 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• Weber M. The role of the new β-blockers in treating cardiovascular disease. Am. J. Hypertens.18, 169S–176S (2005).
   PubMed Web of Science ®Google Scholar
• Gielen W, Cleophas TJ, Agrawal R. Nebivolol. A review of its clinical and pharmacological characteristics. Int. J. Clin. Pharmacol. Ther.44, 344–357 (2006).
   PubMed Web of Science ®Google Scholar
• Prichard BNC. Pharmacologic aspects of intrinsic sympathomimetic activity in β-blocking drugs. Am. J. Cardiol.59, 13F–17F (1987).
   Google Scholar
• McDevitt DG. Pharmacologic aspects of cardioselectivity in a β-blocking drug. Am. J. Cardiol.59, 10F–12F (1987).
   Google Scholar
• Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation101, 558–569 (2000).
   PubMed Web of Science ®Google Scholar
• Bristow M. Characterization of β1-adrenergic receptor selectivity of nebivolol and various β-blockers in human myocardium. Am. J. Hypertens.18(Pt 2), 51A–52A (2005).
   Google Scholar
• Moen MD, Wagstaff AJ. Nebivolol. A review of its use in the management of hypertension and chronic heart failure. Drugs66, 1389–1409 (2006).
   PubMed Web of Science ®Google Scholar
• Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation β-blocker. Blood Pressure13(S1), 3–17 (2004).
   Google Scholar
• Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmac.38, 199–204 (1994).
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther.274, 1067–1071 (1995).
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation104, 511–514 (2001).
   PubMed Web of Science ®Google Scholar
• Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey (1988–1991). Hypertension25, 305–313 (1995).
   PubMed Web of Science ®Google Scholar
• Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J. Am. Coll. Cardiol.40, 754–760 (2002).
   PubMed Web of Science ®Google Scholar
• McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo.Hypertension44, 305–310 (2004).
   PubMed Web of Science ®Google Scholar
• Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation112, 3795–3801 (2005).
   PubMed Web of Science ®Google Scholar
• Pasini AF, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens.23, 589–596 (2005).
   PubMed Web of Science ®Google Scholar
• Falciani M, Rinaldi B, D’Agostino B et al. Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol.38, 922–929 (2001).
   PubMed Web of Science ®Google Scholar
• Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res.49, 430–439 (2001).
   PubMed Web of Science ®Google Scholar
• Pessina AC. Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol.38(Suppl. 3), 33–35 (2001).
   Google Scholar
• Poirier L, Cléroux J, Nadeau A et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens.19, 1429–1435 (2001).
   PubMed Web of Science ®Google Scholar
• Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective β1-adrenoceptor antagonist, nebivolol. Cardiovasc. Drug Rev.22, 155–168 (2004).
   PubMed Web of Science ®Google Scholar
• Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens.24, 591–596 (2006).
   PubMed Web of Science ®Google Scholar
• Uhlir O, Dvorak I, Gregor P et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J. Card. Fail.3, 271–276 (1997).
   PubMedGoogle Scholar
• Dal Negro RW, Tognella S, Micheletto C. Pharmacokinetics of the effect of nebivolol 5mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension: a randomized, placebo-controlled study. Clin. Drug Invest.22, 197–204 (2002).
   Web of Science ®Google Scholar
• Dal Negro RW, Tognella S, Pomari C. Once-daily nebivolol 5mg doses does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension: a placebo-controlled crossover study. Clin. Drug Invest.22, 361–367 (2002).
   Web of Science ®Google Scholar
• Kamali F, Howes A, Thomas SH et al. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br. J. Clin. Pharmacol.43, 201–204 (1997).
   PubMed Web of Science ®Google Scholar
• Shaw AA, Ziemniak J, Liu S et al. Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers [abstract]. Clin. Pharmacol. Ther.77, 77 (2005).
   Google Scholar
• Cheymol G, Woestenborghs R, Snoeck E et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur. J. Clin. Pharmacol.51, 493–498 (1997).
   PubMed Web of Science ®Google Scholar
• Gu Z, Robinson RA, Cai L et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes [abstract]. AAPS PharmSci5, T3362 (2003).
   Google Scholar
• Janssens WJ, Snoeck E. Pharmacology and pharmacokinetics of nebivolol. Symposium on endothelium in hypertension. New Therapeutic Trends.1, 10–13 (1997).
   Google Scholar
• Lawrence TE, Liu S, Fisher JW et al. No interaction between nebivolol and digoxin in healthy volunteers [abstract]. Clin. Pharmacol. Ther.77, 76 (2005).
   PubMed Web of Science ®Google Scholar
• Lawrence TE, Chien C, Tu HC et al. Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffected by nebivolol in healthy volunteers [abstract]. Clin. Pharmacol. Ther.77, 39 (2005).
   Web of Science ®Google Scholar
• Lawrence TE, Chien C, Tu HC et al. No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status [abstract]. Clin. Pharmacol. Ther.77, 82 (2005).
   Web of Science ®Google Scholar
• Morton TL, Tu HC, Liu S et al. Lack of pharmacokinetic interaction between nebivolol and spironolactone [abstract]. Clin. Pharmacol. Ther.77(2), 46 (2005).
   Google Scholar
• Morton TL, Liu S, Phillips JL et al. Pharmacokinetics of nebivolol and ramipril are not affected by co-administration [abstract]. Clin. Pharmacol. Ther.77, 77 (2005).
   Web of Science ®Google Scholar
• Morton TL, Liu S, Phillips JL et al. No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects [abstract]. Clin. Pharmacol. Ther.77, 79 (2005).
   Google Scholar
• Shaw AA, Liu S, Zachwieja LF et al. Effect of chronic administration of fluoxetine on the pharmacokinetics of nebivolol [abstract]. Clin. Pharmacol. Ther.77, 38 (2005).
   Google Scholar
• Van Bortel LMAB, Breed JGS, Joosten J, Kragten JA, Lustermans FATh, Mooij JMV. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J. Cardiovasc. Pharmacol.21, 856–862 (1993).
   PubMed Web of Science ®Google Scholar
• Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J. Hum. Hypertens.11, 139–144 (1997).
   PubMed Web of Science ®Google Scholar
• Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild to moderate hypertension. J. Clin. Hypertens.9, 667–676 (2007).
   PubMedGoogle Scholar
• Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J. Clin. Hypertens.9, 866–875 (2007).
   PubMedGoogle Scholar
• Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J. Hum. Hypertens.12, 135–140 (1998).
   PubMed Web of Science ®Google Scholar
• Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc. Drugs Ther.17, 257–263 (2003).
   PubMed Web of Science ®Google Scholar
• Uhlir O, Fejfusa M, Havranek K et al. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest.3(S1), 107–110 (1991).
   Google Scholar
• Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RHG. Nitric oxide, erectile dysfunction and β-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharm. Phys.34, 327–331 (2007).
   PubMed Web of Science ®Google Scholar
• Van Nueten L, Lacourciere Y, Vyssoulis G et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized comparative trial. Am. J. Ther.5, 237–243 (1998).
   PubMedGoogle Scholar
• Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina C. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press.11, 182–188 (2002).
   PubMed Web of Science ®Google Scholar
• Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JIS. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J. Hum. Hypertens.11, 813–819 (1997).
   PubMed Web of Science ®Google Scholar
• Rosei EA, Rizzoni D, Comini S, Boari G. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press.12(S1), 30–35 (2003).
   Web of Science ®Google Scholar
• Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am. J. Hypertens.18, 1060–1066 (2005).
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am. J. Hypertens.7, 137–145 (1994).
   PubMed Web of Science ®Google Scholar